Amgen is getting aggressive with one of its midstage leukemia drugs. In its earnings call with analysts the big biotech’s R&D chief called out blinatumomab, saying that recent Phase II data might warrant an early approval.

…read more

Source: Amgen beats a path to the FDA, looking for an early approval of leukemia drug


0 No comments